Elevance Health, Inc. $ELV Shares Acquired by CenterBook Partners LP

CenterBook Partners LP increased its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 20.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,078 shares of the company’s stock after purchasing an additional 2,033 shares during the quarter. CenterBook Partners LP’s holdings in Elevance Health were worth $3,903,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MJP Associates Inc. ADV boosted its stake in shares of Elevance Health by 12.3% during the 3rd quarter. MJP Associates Inc. ADV now owns 1,715 shares of the company’s stock worth $554,000 after purchasing an additional 188 shares during the last quarter. Vista Investment Management lifted its stake in shares of Elevance Health by 18.3% during the third quarter. Vista Investment Management now owns 5,529 shares of the company’s stock valued at $1,787,000 after buying an additional 856 shares during the period. Beirne Wealth Consulting Services LLC acquired a new stake in Elevance Health during the third quarter worth approximately $466,000. Timber Creek Capital Management LLC grew its stake in Elevance Health by 32.0% in the 3rd quarter. Timber Creek Capital Management LLC now owns 16,652 shares of the company’s stock worth $5,380,000 after acquiring an additional 4,034 shares during the period. Finally, NEOS Investment Management LLC raised its holdings in Elevance Health by 45.8% in the 3rd quarter. NEOS Investment Management LLC now owns 28,971 shares of the company’s stock valued at $9,361,000 after acquiring an additional 9,101 shares during the last quarter. 89.24% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ELV. TD Cowen restated a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Mizuho set a $413.00 price target on shares of Elevance Health in a report on Friday, January 9th. Barclays lowered their price objective on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating for the company in a research note on Friday, January 30th. Guggenheim cut their target price on Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a research report on Thursday, January 29th. Finally, Leerink Partners lifted their target price on Elevance Health from $350.00 to $357.00 and gave the company a “market perform” rating in a report on Thursday, January 29th. Twelve research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and an average target price of $390.55.

Elevance Health Trading Up 0.4%

NYSE ELV opened at $346.31 on Thursday. The stock has a market cap of $76.43 billion, a P/E ratio of 13.79, a PEG ratio of 1.92 and a beta of 0.50. The company’s fifty day simple moving average is $352.94 and its 200-day simple moving average is $333.33. The company has a current ratio of 1.54, a quick ratio of 1.54 and a debt-to-equity ratio of 0.70. Elevance Health, Inc. has a 52 week low of $273.71 and a 52 week high of $458.75.

Elevance Health (NYSE:ELV) last released its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating analysts’ consensus estimates of $3.10 by $0.23. The business had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The business’s revenue was up 9.6% on a year-over-year basis. During the same period last year, the business earned $3.84 EPS. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current fiscal year.

Elevance Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Investors of record on Tuesday, March 10th will be issued a $1.72 dividend. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, March 10th. Elevance Health’s dividend payout ratio (DPR) is currently 27.23%.

Elevance Health Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.